A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 205 shares of EDIT stock, worth $256. This represents 0.0% of its overall portfolio holdings.

Number of Shares
205
Previous 205 -0.0%
Holding current value
$256
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 05, 2024

BUY
$4.67 - $7.28 $957 - $1,492
205 New
205 $0

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $85.9M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Thurston, Springer, Miller, Herd & Titak, Inc. Portfolio

Follow Thurston, Springer, Miller, Herd & Titak, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thurston, Springer, Miller, Herd & Titak, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Thurston, Springer, Miller, Herd & Titak, Inc. with notifications on news.